禾元生物明日申购 顶格申购需配市值14.00万元

Core Viewpoint - He Yuan Bio is set to launch its public offering, with a total share capital of 268 million shares and plans to issue 89.45 million shares, representing 25.02% of the post-issue total share capital [2] Company Information - He Yuan Bio is an innovative biopharmaceutical company with a leading global plant bioreactor technology platform [2] - The company plans to issue shares at a price of 29.06 yuan, with a maximum subscription limit of 14,000 yuan in market value required for top-tier subscriptions [2] Fundraising Allocation - The company intends to allocate raised funds as follows: - 1.90 billion yuan for the construction of a plant-derived recombinant human serum albumin industrialization base - 793.69 million yuan for new drug research and development - 800 million yuan for working capital [2] Financial Indicators - Key financial metrics for He Yuan Bio include: - Total assets for 2024 are projected at 1.0618 billion yuan, compared to 962.20 million yuan in 2023 and 1.1027 billion yuan in 2022 - Net assets are expected to be 601.35 million yuan in 2024, down from 731.62 million yuan in 2023 and 895.26 million yuan in 2022 - Operating revenue is forecasted at 25.22 million yuan for 2024, slightly up from 24.26 million yuan in 2023 and significantly higher than 13.40 million yuan in 2022 - The company anticipates a net loss attributable to shareholders of 151.37 million yuan in 2024, an improvement from a loss of 186.96 million yuan in 2023 and 143.57 million yuan in 2022 - Research and development expenses are projected at 116.79 million yuan for 2024, with R&D expenditure as a percentage of operating revenue at 463.14% [2]